Potential Switzerland (Swissmedic) approval of Amtagvi
Iovance Biotherapeutics expects regulators to decide on lifileucel (Amtagvi) for advanced melanoma in the first half of 2027 (no exact date yet). An approval lets the company start selling it in that market.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary
- Company
- Iovance Biotherapeutics, Inc. IOVA
- Drug
- lifileucel (Amtagvi)
- For
- advanced melanoma
- Stage
- Regulatory review
- When
- H1 2027 · the company gave a window, not a day; the calendar never invents one
- Source note
- Company guidance: Switzerland approval "expected in 1H27".
- Checked
- Checked by a person when it was added
- Source: biospace.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- Drugs@FDA ↗ — search the drug name for approval letters
- IOVA headlines on this site
Iovance Biotherapeutics expects UK regulators to decide on lifileucel (Amtagvi) for advanced melanoma in the second half of 2026 (no exact date yet). An approval lets the company start selling it in that market.
More details
- Entry
- Potential UK (MHRA) approval of Amtagvi in advanced melanoma · Regulatory approval
- Drug
- lifileucel (Amtagvi)
- For
- advanced melanoma
- Stage
- Regulatory review (expedited MHRA pathway)
- When
- H2 2026 · the company gave a window, not a day
- Source note
- Company guidance: potential UK approval "later in 2026" via expedited MHRA review.
- Checked
- Checked by a person when it was added
- Verify it
- Source: biospace.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- Drugs@FDA ↗ — search the drug name for approval letters
- IOVA headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Iovance Biotherapeutics presents data on lifileucel (Amtagvi) / TIL therapy for undifferentiated pleomorphic sarcoma / dedifferentiated liposarcoma (UPS/DDLPS) at a medical meeting in Oct 2026 (no exact date yet). New numbers at a conference can move the stock as much as a formal announcement.
More details
- Entry
- SARATOGA data oral presentation at ESMO 2026 · Data presented at a medical meeting
- Drug
- lifileucel (Amtagvi) / TIL therapy
- For
- undifferentiated pleomorphic sarcoma / dedifferentiated liposarcoma (UPS/DDLPS)
- Stage
- Clinical trial results
- When
- Oct 2026 · the company gave a window, not a day
- Source note
- Results to be highlighted in an oral presentation at the European Society for Medical Oncology (ESMO) meeting in Madrid, October 23-27, 2026, per company Q2 2026 press release.
- Checked
- Checked by a person when it was added
- Verify it
- Source: biospace.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- IOVA headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Iovance Biotherapeutics presents data on lifileucel (Amtagvi) + pembrolizumab for frontline advanced melanoma at a medical meeting in Oct 2026 (no exact date yet). New numbers at a conference can move the stock as much as a formal announcement.
More details
- Entry
- TILVANCE-301 lifileucel + pembrolizumab frontline melanoma oral at ESMO 2026 · Data presented at a medical meeting
- Drug
- lifileucel (Amtagvi) + pembrolizumab
- For
- frontline advanced melanoma
- Stage
- Phase 3 · the last stage before a drug can be approved
- When
- Oct 2026 · the company gave a window, not a day
- Source note
- Q2 2026 results PR (Aug 6, 2026). ESMO 2026 runs Oct 23-27 in Madrid. Separate from the SARATOGA oral (#3725RO) already tracked.
- Checked
- Checked by a person when it was added
- Verify it
- Source: biospace.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- IOVA headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Iovance Biotherapeutics expects to report results from its Phase 2 study of lifileucel for post-anti-PD-1 metastatic nonsquamous NSCLC in Q4 2026 (Oct–Dec) (no exact date yet). Phase 2 is the stage that tests whether the drug actually works.
More details
- Entry
- IOV-LUN-202 NSCLC registrational program updates · Clinical trial results (readout / topline data)
- Drug
- lifileucel
- For
- post-anti-PD-1 metastatic nonsquamous NSCLC
- Stage
- Phase 2 · the stage that tests whether the drug actually works
- When
- Q4 2026 · the company gave a window, not a day
- Source note
- Enrollment nearly complete in the pivotal cohorts; "program updates are expected in 4Q26" per Q2 2026 press release. Fast Track designation granted.
- Checked
- Checked by a person when it was added
- Verify it
- Source: biospace.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- IOVA headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Iovance Biotherapeutics expects to report results from its investigator-sponsored study of lifileucel for CSCC / MCC in the first half of 2027 (no exact date yet). This is the first look at whether the drug did what the company hoped.
More details
- Entry
- Initial lifileucel data in cutaneous SCC and Merkel cell carcinoma · Clinical trial results (readout / topline data)
- Drug
- lifileucel
- For
- CSCC / MCC
- Stage
- investigator-sponsored
- When
- H1 2027 · the company gave a window, not a day
- Source note
- Q2 2026 results PR (Aug 6, 2026). Investigator-sponsored trials.
- Checked
- Checked by a person when it was added
- Verify it
- Source: biospace.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- IOVA headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Amtagvi sBLA submission in nonsquamous NSCLC (IOV-LUN-202), expected during 2027 (no exact date yet). A company milestone for Iovance Biotherapeutics (lifileucel (Amtagvi) for post-anti-PD-1 metastatic nonsquamous NSCLC): a step in the program rather than a decision or a data readout.
More details
- Entry
- Amtagvi sBLA submission in nonsquamous NSCLC (IOV-LUN-202) · Company milestone
- Drug
- lifileucel (Amtagvi)
- For
- post-anti-PD-1 metastatic nonsquamous NSCLC
- Stage
- sBLA planned
- When
- 2027 · the company gave a window, not a day
- Source note
- "A supplemental Biologics License Application (sBLA) submission is planned in 2027" (year-level guidance only).
- Checked
- Checked by a person when it was added
- Verify it
- Source: biospace.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- IOVA headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page